DOWNSIZED covers effects of the experimental triple agonist retatrutide other than weight loss, as the channel describes them.
Recap by typeshit. Full story at DOWNSIZED.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
%20copy.jpg)
Dermatologists tell Vogue that signal and carrier peptides, like copper peptides, have the most evidence behind their anti-aging claims.
Millions of Medicare beneficiaries may want in on the GLP-1 Bridge program, but eligibility rules mean not everyone will qualify.
Loading…